Holen Sie sich die Stockscreener-App
7.735
0.47%
-0.015
Schlusskurs vom Vortag:
$7.75
Offen:
$7.85
24-Stunden-Volumen:
18,552
Relative Volume:
0.20
Marktkapitalisierung:
$401.96M
Einnahmen:
$154.57M
Nettoeinkommen (Verlust:
$15.07M
KGV:
28.65
EPS:
0.27
Netto-Cashflow:
$10.92M
1W Leistung:
-2.97%
1M Leistung:
+12.61%
6M Leistung:
+26.66%
1J Leistung:
+59.70%
1-Tages-Spanne:
$7.6654
$7.855
1-Wochen-Bereich:
$7.6654
$7.94
52-Wochen-Spanne:
$4.93
$9.155
Kamada Ltd Stock (KMDA) Company Profile
Vergleichen Sie KMDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
7.775 | 401.96M | 154.57M | 15.07M | 10.92M | 0.27 |
|
RGC
Regencell Bioscience Holdings Ltd
|
16.04 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
160.56 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.37 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.47 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.86 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Eingeleitet | The Benchmark Company | Buy |
| 2024-07-03 | Eingeleitet | Stifel | Buy |
| 2018-02-02 | Eingeleitet | Chardan Capital Markets | Buy |
Kamada Ltd Aktie (KMDA) Neueste Nachrichten
Should Value Investors Buy Kamada (KMDA) Stock? - Yahoo Finance
Kamada Confirms Continuous Global Business Operations and - GlobeNewswire
Kamada Ensures Global Operations Amid Middle East Tensions - TipRanks
Kamada confirms continuous business operations despite Middle East events - TipRanks
Kamada Confirms No Supply Disruptions: How Israeli Biotech Giant Safeguards Global Product Availability - Stock Titan
Kamada Reports Strong Q1 2025 Growth with Plasma Business Expansion and Key Milestones - citybuzz -
Implied Volatility Surging for Kamada Stock Options - Yahoo Finance
Kamada Intensifies Efforts to Highlight CYTOGAM's Role in Combatting CMV in Organ Transplant Patients - citybuzz -
Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAM - FinancialContent
Millennium Management LLC Sells 36,872 Shares of Kamada Ltd. (NASDAQ:KMDA) - Defense World
Are Investors Undervaluing Kamada (KMDA) Right Now? - Yahoo Finance
Alpha-1 Antitrypsin Deficiency Market: Epidemiology, - openPR.com
Kamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Kamada (NASDAQ:KMDA) Stock Rating Upgraded by Wall Street Zen - Defense World
Kamada's (TLV:KMDA) Solid Earnings Are Supported By Other Strong Factors - simplywall.st
Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm - The Manila Times
HC Wainwright Issues Optimistic Outlook for Kamada Earnings - Defense World
Sidoti Csr Has Optimistic Outlook of Kamada FY2025 Earnings - Defense World
Kamada’s (KMDA) Buy Rating Reiterated at Benchmark - Defense World
Kamada Ltd. (NASDAQ:KMDA) Q1 2025 Earnings Call Transcript - MSN
Is Kamada (KMDA) Stock Undervalued Right Now? - Yahoo Finance
Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade - Yahoo Finance
Kamada Ltd’s Earnings Call Highlights Strong Growth and Expansion - TipRanks
Kamada (KMDA) Receives Reiterated Buy Rating from Benchmark | KM - GuruFocus
Kamada (KMDA) Receives Reiterated Buy Rating from Benchmark | KMDA Stock News - GuruFocus
Benchmark maintains Kamada stock Buy rating with $15 target By Investing.com - Investing.com Nigeria
Kamada: Q1 Earnings Snapshot - CT Insider
Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - Yahoo
Benchmark maintains Kamada stock Buy rating with $15 target - Investing.com
Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Kamada Ltd. Reports Strong Q1 2025 Results - TipRanks
Kamada Q1 2025 Earnings Call Transcript - MarketBeat
Compared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Kamada Reports Strong First Quarter 2025 Financial Results with - GuruFocus
Kamada Reports Strong Q1 2025 Financial Results and Expands Plasma Operations - TipRanks
Kamada Reports Strong First Quarter 2025 Financial Results - GlobeNewswire
Inter Alpha Inhibitor Treatment Market Size in 7MM is expected - openPR.com
Kamada (KMDA) Projected to Post Quarterly Earnings on Wednesday - Defense World
Kamada (NASDAQ:KMDA) Upgraded at Sidoti - Defense World
Kamada (KMDA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025 - GlobeNewswire
Kamada Ltd. to report Q1 2025 financial results on May 14 - Investing.com Nigeria
Kamada to Release Q1 2025 Financial Results on May 14 - TipRanks
JPMorgan Chase & Co. Invests $67,000 in Kamada Ltd. (NASDAQ:KMDA) - Defense World
Kamada Launches Post-Marketing Research Program for CYTOGAM - TipRanks
Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM® - GlobeNewswire
Major Breakthrough: Kamada Initiates 10 Clinical Studies to Transform Organ Transplant CMV Treatment - Stock Titan
Geode Capital Management LLC Raises Position in Kamada Ltd. (NASDAQ:KMDA) - Defense World
Finanzdaten der Kamada Ltd-Aktie (KMDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):